Numerous experimental and clinical studies [reviewed in (1) (2) (3) ] have shown that repeated injections of low doses of exogenous cytokines in the area of a growing tumor can activate an antitumor reaction and induce a tumor-specific immune memory. Similar but more efficient reactions are activated by cytokine gene-engineered cells (i.e., ''engineered cells'') (2) . When used as a vaccine, engineered cells induce a strong immune memory that inhibits a subsequent challenge with wildtype parental tumor cells (2, 4) . Although the efficacy of tumors previously classified as poorly immunogenic or nonimmunogenic is usually marginal when they are employed to cure mice harboring established tumors (2, 5, 6) , they can be modified and used to generate an effective immune memory (2, 7) .
Various cytokines are being evaluated to improve the immunogenic capacity of tumors. Interleukin (IL)-12 is of particular interest because it has a unique heterodimeric structure and a long half-life and because it plays an important role in regulating the immune response by both acting as an adjuvant and promoting the generation of T helper 1 (Th1) and cytotoxic lymphocytes. The immune reaction that IL-12 elicits stems from the induction of interferon gamma (IFN ␥) and is governed by T cells and natural killer cells (8) . Moreover, IL-12 seems to act chiefly in those sites where T lymphocytes have been activated and have accumulated, as shown in the case of experimental autoimmune diseases (9) .
Animal model studies have demonstrated that fibroblasts engineered to release IL-12 admixed with tumor cells (10, 11) and direct transduction of IL-12 genes into a variety of mouse tumors (12) (13) (14) inhibit tumor growth and induce antitumor immunity. On the other hand, systemic and peritumoral administration of exogenous recombinant IL-12 (rIL-12) markedly inhibits the growth of many tumors of different histotypes and immunogenicities and leads to the development of an effective systemic antitumor response (15) (16) (17) (18) (19) (20) .
The experimental observation that engineered cells elicit an immune memory against the wild-type parental tumor has prompted their use as anticancer vaccines in several trials [reviewed in (21) ]. Unfortunately, the rationale for these clinical trials is often based on enthusiasm prompted by findings limited to cells engineered to release a single cytokine (2, 21) , and few comparative studies have been performed (4, 5, 22, 23) . Comparison is of particular importance with respect to IL-12 because of its potent antitumor effects.
This article offers further evidence of the antitumor efficacy of IL-12, as revealed by a comparison of the immunity conferred by the cells of an aggressive, metastasizing, and moderately differentiated spontaneous mammary adenocarcinoma (TSA) (24) . The efficacy of the antitumor reaction elicited by TSA cells engineered to release IL-12 (TSA-IL12) was compared with both that elicited by TSA cells engineered to release other cytokines and that elicited by local and systemic administrations of exogenous rIL-12.
Materials and Methods
Tumors and in vitro cultures. TSA is an aggressive and poorly immunogenic cell line established from the first in vivo transplant of a moderately differentiated mammary adenocarcinoma that arose spontaneously in a 20-month-old multiparous BALB/c mouse (provided by Dr. P. Nanni, Istituto di Cancerologia, University of Bologna, Italy) (24) . Several vials of the 8th in vitro passage of the TSA parental cells (TSA-pc) were stored in liquid nitrogen before thawing and cultured by one or two passages in vitro. TSA cells express major histocompatibility complex class I, but not class II, molecules (25) ; they secrete granulocyte and granulocyte-macrophage colony-stimulating factors (GMCSFs) [as do the majority of human and mouse mammary adenocarcinomas (26) ] and transforming growth factor ␤1 (25). TSA-pc do not stimulate a syngeneic antitumor response in vivo or in vitro in mixed lymphocyte-tumor cell cultures (1, 27) . F1-F is a fibroblast cell line derived from the skin of a newborn BALB/c mouse; it spontaneously transformed after the 15th in vitro passage (25) . Previous experiments showed that F1-F does not immunologically crossreact with TSA-pc, and it was used as a control cell type (27) . Confluent monolayers of TSA and F1-F cells treated with a 0.25% solution of trypsin (Sigma Chemical Co., St. Louis, MO) in phosphate-buffered saline were used for in vitro and in vivo experiments. In BALB/c mice, 4 × 10 4 and 1 × 10 4 , respectively, are the minimal 100% TSA-pc and F1-F tumor-inducing doses (7, 27) . In a few experiments, mice were immunized with TSA cells admixed with 100 g of Corynebacterium parvum (TSA-CP) (Wellcome, London, U.K.) or emulsified with 250 L of complete Freund's adjuvant (TSA-CFA) (Difco Laboratories, Inc., Detroit, MI). Cells were cultured in sterile, disposable glassware (Nunc, Roskilde, Denmark) at 37°C in a humidified 5% CO 2 atmosphere, with the use of RPMI-1640 medium supplemented with 10% fetal calf serum and 50 g/mL gentamicin (all from Whittaker Bioproducts, Milan, Italy).
Gene transduction. TSA-pc were transduced with mouse cytokine genes, as previously reported: IL-2 (7), IL-4 (27), IL-6 (6), IL-7 (22), IL-10 (25), GMCSFs (6), interferon alfa (IFN ␣) (23), IFN ␥ (28), and tumor necrosis factor (TNF)-␣ (6). TSA-IL12 cells transduced with the polycistronic LmIL-12SN retroviral vector coding for both murine IL-12 subunits were obtained as previously described for another murine adenocarcinoma (29) . Transduced TSA cells were then cultured and cloned by limiting dilution in selective medium, and the single-cell clones were expanded and subcloned. The amount of cytokine produced by 1 × 10 5 engineered cells after 48 hours of culture in 1 mL of medium was evaluated by use of enzyme-linked immunoassay kits that are specific for individual cytokines (IL-6, IL-10, GM-CSF, and TNF-␣ [Endogen Inc., Boston, MA] and IL-12 [L. Adorini, Hoffmann-La Roche at the Istituto S. Raffaele, Milan]) or a biologic assay [IL-2 (7), IL-4 (27), IL-7 (6), IFN ␣ (23), or IFN ␥ (28)]. When available, a standard of a known amount of each cytokine was included in these assays to express the data as units per milliliter of cytokine produced. We selected a representative clone releasing in the above-specified conditions the amount of cytokine (IL-2, 3600 U/mL; IL-4, 40 U/mL; IL-6, 1250 U/mL; IL-7, 30 U/mL; IL-10, 620 U/mL; IL-12, 25 ng/mL; GM-CSF, 12 ng/mL; IFN ␣, 200 U/mL; IFN ␥, 6000 U/mL; TNF-␣, 10 U/mL) that most efficaciously elicits an immune response to a subsequent TSA-pc challenge (6, 22) . TSA-neo is a control cell clone that has been stably transfected with the neomycin resistance gene only (7) . When nonproliferating cells were required, TSA-pc and clones were treated with 60 g/mL of mitomycin C (Sigma Chemical Co.) per 1 × 10 7 cells/mL for 30 minutes at 37°C. Comparative immunization and cure experiments performed with nonproliferating TSA cells irradiated with 50 000 rad from a 137 Cs source gave similar results (6) and are not shown. Administration of exogenous mouse rIL-12. Groups of mice were treated with various doses of mouse rIL-12 (Hoffmann-La Roche, Nutley, NJ) diluted in phosphate-buffered saline containing 100 g/mL mouse serum albumin (Sigma Chemical Co.) and injected either locally at the site of subcutaneous tumor growth or intraperitoneally. Starting 1 or 7 days after challenge, mice received two courses of five daily injections at 2-day intervals. Except when otherwise indicated, mice received 0.1 g rIL-12 per day. Control mice received the same volume of phosphate-buffered saline containing serum albumin only.
Mice. Seven-week-old female BALB/cAnCr mice syngeneic with TSA cells (Charles River Laboratories, Calco, Italy) were treated properly and humanely in accordance with the European Union guidelines. Starting 2 days before and 4 hours after tumor challenge and then at 2-week intervals, groups of a few mice each received intraperitoneal injections of 0.2 mL of phosphate-buffered saline containing a 1/20 dilution of one of the following: anti-asialoganglioside GM 1 rabbit antiserum (anti-asialo GM 1 ; Wako Chemicals, Dusseldorf, Germany), 100 g anti-CD4 (GK1.5 hybridoma, L3T4; American Type Culture Collection [ATCC], Rockville, MD), anti-CD8 (TIB-105 hybridoma, Lyt 2; ATCC), antipolymorphonuclear leukocyte monoclonal antibodies (RB6-8C5 hybridoma; provided by Dr. R. L. Coffman, DNAX Inc., Palo Alto, CA), or normal rat immunoglobulins purified from serum or ascitic fluid by passage through an anionic exchange column (DE52; Whatman Ltd., Maidstone, U.K.). Cytofluorimetric analysis of the blood and spleen cells from mice receiving these antibodies showed that target leukocytes were selectively decreased to fewer than 1/5000 of peripheral blood leukocytes during treatment. Immunosuppressed mice received sterilized food pellets and tap water ad libitum and were maintained under specific-pathogen-free conditions.
In vivo evaluation of tumor growth. Mice were challenged (i.e., inoculated) subcutaneously in the middle of the left (primary challenge) or right (secondary challenge) flank with 0.2 mL of a single-cell suspension containing the indicated number of tumor cells. The cages were coded, and the incidence and growth of tumors were evaluated twice weekly in a blinded fashion. Neoplastic masses were measured with calipers in the two perpendicular diameters. Mice free of tumor 120 days after challenge were classified as survivors. Latency and survival times were considered as the periods (in days) between challenge and the growth of neoplastic masses of 3 and 10 mm in mean diameter, respectively. Only mice that eventually developed tumor were considered. Mice were killed for humane reasons when the tumor exceeded 10 mm in mean diameter.
Morphologic analysis. For histologic evaluation, tissue samples from groups of five mice each that were killed 1, 2, or 4 days after TSA-IL12 tumor cell challenge or after three daily intraperitoneal injections of rIL-12 performed starting 1 or 7 days after TSA-pc challenge were fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned at 4 m, and stained with hematoxylin-eosin or Giemsa. For electron microscopy, specimens were fixed in cacodylate-buffered 2.5% glutaraldehyde, postfixed in osmium tetroxide, and then embedded in epoxy resin. Ultrathin sections (0.75 m) were stained with uranyl acetate-lead citrate. For immunohistochemistry, acetone-fixed cryostat sections were incubated for 30 minutes with the following rat monoclonal antibodies: anti-CD4 and anti-CD8 (both from Sera-Lab, Crawley Down, Sussex, U.K.); anti-MAC-1 (anti-CD11b/CD18), anti-MAC-3, and anti-Ia (all from Boehringer Mannheim, Milan); anti-granulocytes (RB6-8C5); and anti-endothelial cell (MEC-13.3; provided by Dr. A. Vecchi, Mario Negri Institute, Milan) (30) . After being washed with phosphate-buffered saline, the sections were overlaid with biotinylated rabbit anti-rat immunoglobulins (Vector Laboratories, Burlingame, CA) for 30 minutes. Unbound immunoglobulins were removed by being washed with phosphate-buffered saline, and the slides were incubated with avidin-biotin complex/alkaline phosphatase (Dako, Glostrup, Denmark).
Statistical analysis. All in vivo experiments were performed three or more times with groups of five mice each, and the data from these experiments were combined because they gave homogeneous results. The significance of differences in tumor takes was determined by Fisher's exact test or Pearson's chisquared test, depending on the size of the groups.
Results

Oncogenicity of TSA-IL12 Cells in Syngeneic Mice
The in vitro doubling times of the engineered TSA clones were not substantially different from those of TSA-neo and TSA-pc, suggesting that the cytokine released has no major direct effect on TSA cell proliferation (data not shown). However, since many paracrine cytokines inhibit tumor growth by activating a host response, we compared the ability of TSA-IL12 to form tumors with that of TSA cells engineered to release other cytokines ( Fig. 1 ). Mice were inoculated with 1 × 10 5 TSA cells, a dose 2.5 times higher than the minimal dose of TSA-pc necessary for producing tumors in 100% of the animals. Inoculations of equivalent numbers of TSA-pc, TSA-neo cells, or TSA cells engineered to release IL-5, IL-6, GM-CSF, or IFN ␥ gave rise to tumors in all or in the majority of mice. By contrast, inoculations of TSA cells engineered to release IL-4, IL-7, IL-10, IL-12, IFN ␣, or TNF-␣ led to tumor formation in only a minority of the animals in each treatment group. None of the 40 mice inoculated with TSA cells engineered to produce IL-2 developed tumors.
The local cell tissue reaction associated with the inhibition of TSA cells engineered to release IL-2, IL-4, IL-7, IL-10, TNF-␣, IFN ␣, and IFN ␥ has been previously studied in detail (7, 22, 23, 25, 27, 28) . To gain an insight into the mechanisms associated with the rejection of TSA-IL12 cells and to compare these mechanisms with those previously described, we killed the mice 1, 2, or 4 days after challenge and processed the tumor area for light and electron microscopy. One and 2 days after the challenge, most TSA-IL12 cells were scattered and displayed morphologic features of both reversible and irreversible injuries frequently associated with unequivocal necrosis (Fig. 2) . Only a few TSA-IL12 cell aggregates could be found. The blood vessel walls around the tumor mass were damaged, and foci of hemorrhage were seen. In the peripheral and intratumoral areas, both the presence of several macrophages and polymorphonuclear leukocytes and the various lymphocytes were shown by histologic, immunohistochemical, and ultrastructural observations. At day 4, the tumor was replaced by granulation tissue, while the draining regional lymph node showed a marked paracortical hyperplasia (data not shown).
To assess functionally the relative importance of the reactive leukocyte populations, we injected TSA-IL12 cells into mice that had been selectively immunodepressed by in vivo treatment with antibodies specific for different leukocyte populations. Removal of polymorphonuclear leukocytes and natural killer cells did not influence the rejection of TSA-IL12 cells, whereas the absence of CD8-positive lymphocytes allowed TSA-IL12 cells to form tumors in about 80% of the mice (Fig. 3) . It is interesting that the removal of CD4-positive lymphocytes alone or together with CD8-positive lymphocytes decreased the establishment of tumors (Fig. 3) . This finding fits well with the observed negative role of CD4-positive lymphocytes in the reaction elicited by tumor cells engineered to release IL-12 as described by Martinotti et al. (14) .
Ability of TSA-IL12 Cells to Preimmunize Against TSA-pc Challenge
The ability of engineered cells to elicit an efficient systemic immune memory against tumor parental cells forms the rationale for their use as vaccines (2,21 These experiments were designed solely to evaluate the efficacy of the reaction elicited by the local release of cytokines and not to compare nonproliferating and proliferating cells. However, the 10 times higher dose of nonproliferating cells was used to provide a higher cytokine production and antigen load and thus to reduce the disadvantage stemming from their inability to expand (6) . Mice immunized with nonproliferating cells and mice having no palpable tumors after the challenge with proliferating TSA cells were subsequently challenged subcutaneously in the right flank with a lethal dose of TSA-pc (Fig. 4, upper panel) .
Only a slight protection was afforded by preimmunization with nonproliferating cells. By protecting 36% of the mice studied, nonproliferating TSA-IL12 cells appeared to be the most effective. However, as observed in the TSA tumor model (6) and in other tumor systems (31), the growth and rejection of proliferating TSA engineered cells appear to deliver a stronger immunogenic signal. Protection was complete in mice that rejected TSA-IL4 and TSA-IL10 cells and in the few mice that rejected TSA-IFN␥ cells; it ranged between 32% and 60% in mice that rejected TSA-IL2, TSA-IL7, TSA-IL12, or TSA-IFN␣ but was only marginal in those that rejected TSA-TNF␣ cells. Since no mice survived challenge with TSA-pc, TSA-IL5, TSA-IL6, or TSA-GM cells, these cells could not be used as live vaccines. The selectivity of this immune memory was demonstrated by the results of a specificity check with the antigenically unrelated F1-F tumor (data not shown).
Cure of Mice Bearing Established TSA-pc Tumors Through Administration of TSA-IL12 Cells
The ability of TSA engineered cells to elicit systemic immunity against a subsequent tumor challenge was not necessarily associated with their ability to cure the animals of their tumors (5, 6, 27) Local injection of fibroblasts engineered to release IL-12 induces tumor regression (10), even of TSA-pc (11). Starting 1 and 7 days after TSA-pc challenge, therefore, mice received four injections of proliferating and nonproliferating TSA-IL12 cells in the area of the subcutaneous tumor (Fig. 6) . The nonproliferating cells cured 40% of mice bearing a 1-day tumor. The lower effectiveness of the proliferating cells was probably because of their residual ability to grow in vivo ( Fig. 1) and thus contribute to the oncogenic potential of the TSA-pc. Proliferating cells alone retained a marginal (10%) curative ability against 7-day tumors.
Curative Potential of TSA-IL12 Cells Versus Exogenous rIL-12
TSA-IL12 cells appear to be the most efficient engineered cells in the cure of established tumors; this finding is in keeping with reports of the potent curative ability of IL-12-releasing fibroblasts (10,11) and other IL-12-releasing tumor cells (12) (13) (14) . Systemic rIL-12 administration also is a powerful inhibitor of tumor growth (15) (16) (17) (18) (19) (20) and that of TSA-pc in particular (19) . It was thus important to compare the efficacy of TSA-IL12 cells with that of the simpler systemic or local administration of nontoxic doses of rIL-12.
About the same number of mice bearing 1-day TSA-pc tu- 5 proliferating cells were injected four times subcutaneously in the right flank on days +1, +5, +8, and +12 (+1 day tumors) or on days +7, +12, +15, and +19 (+7 day tumors) after TSA-pc challenge. Cured mice are those without palpable left flank tumors at day +120. To the right of each bar is reported in parentheses the number of cured mice/total number of challenged mice. mors were cured by both repeated contralateral administration of proliferating TSA-IL12 cells (Fig. 5) and by two 5-day courses of rIL-12 given intraperitoneally (Fig. 6) . However, only two (13%) of 15 mice bearing 7-day tumors were cured by the same administration of proliferating cells (Fig. 5 ) compared with 24 (80%) of 30 mice bearing 7-day tumors that were cured by two 5-day courses of rIL-12 given intraperitoneally (Fig. 6) . None of these mice were cured by a pulse administration of the maximum tolerated dose of rIL-2 (Fig. 6 ). These findings agree with previous observations (18, 19) that the effects of rIL-12 are more evident against established tumors than against incipient tumors, a situation that may imply dependence on the number of T and natural killer cells preactivated by the tumor.
Repeated local administration of rIL-12 cured 80% of mice with incipient (1-day) tumors, a value higher than that achieved by proliferating and nonproliferating TSA-IL12 cells (Fig. 6) . Dose reductions showed that the curative effect of local rIL-12 decreased by 50%. A marginal reactivity was still evident even when very low doses were injected locally, as was reported for many other cytokines (1, 32) . Moreover, whereas intraperitoneal administration of rIL-12 was more efficacious against large 7-day than against 1-day tumors, local rIL-12 had little effect against 7-day tumors.
Rejection of TSA-pc Tumors Provoked by Systemic rIL-12
The cell events that take place following systemic administration of rIL-12 were investigated by morphologic examination of the tumor rejection area (Fig. 7) . The tumor formed solid aggregates of tumor cells interspersed with areas of coagulative necrosis, and hemorrhage was surrounded by a dense macrophage infiltrate. Marked peripheral and intratumor vascular congestion with focal extravasation of erythrocytes and severe damage of the endothelium lining tumor microvessels were evident. Several vessels were filled with polymorphonuclear leukocytes, and some were occluded by intraluminal thrombi (Fig. 8) . Some lymphocytes and several polymorphonuclear leukocytes were scattered throughout the tumor and near the residual tumor vessels. Functional data in selectively depleted mice also did not disclose a single-cell population responsible for the curative effect of systemic rIL-12, but they did suggest that the cure of 7-day TSA-pc tumors rests mainly on the concurrent activity of CD8-positive lymphocytes and polymorphonuclear leukocytes (Fig. 3) . Removal of natural killer cells, however, reduced the percentage of cured mice. By analogy with what was observed in the reaction to TSA-IL12 cells, the removal of CD4-positive lymphocytes increased the number of cured mice.
Efficacy of Anti-TSA-pc Immune Memory Elicited by TSA-IL12 and Exogenous rIL-12
All mice that rejected 1-day TSA-pc tumors after rIL-12 administration were resistant to a contralateral right flank challenge with a lethal dose of TSA-pc (Fig. 4, lower panel) . A similar, but apparently lower, protection was found in mice challenged with TSA-IL12 and treated with systemic rIL-12. The raising of an efficient memory was not surprising, in view of our earlier finding that the slow growth of incipient tumors and their regression provide a major immunogenic stimulus, no matter how it is obtained (33) .
To ascertain whether rIL-12 also promotes the induction of a memory response, we systemically administered rIL-12 to mice that had been challenged with nonproliferating TSA or TSA-IL12 cells. Under these conditions, rIL-12 did not modulate the growth and rejection of tumor cells but acted as a powerful adjuvant that led to the induction of protective immunity against a subsequent TSA-pc challenge in 80% of the mice. In the presence of systemic rIL-12, the local release of IL-12 by proliferating and nonproliferating TSA-IL12 cells apparently results in a weaker memory induction, probably because the local reaction leads to a quicker disappearance of TSA-IL12 cells compared with that of TSA-pc.
An enhancement of the ability of TSA-pc to elicit a systemic immune memory was also evident when rIL-12 was administered locally at the challenge site with the immunizing TSA-pc and TSA-IL12 cells (Fig. 4) . However, the memory response elicited by local administration of rIL-12 always appeared less efficient than that elicited by the intraperitoneal administration of the same amount of this cytokine.
Discussion
Our findings show that TSA cells engineered to constitutively release a small amount of IL-12 provide a triggering signal that leads to both tumor debulking and induction of a selective immunity to a subsequent challenge by wild-type TSA-pc. However, TSA cells engineered to release small amounts of TNF-␣ and IL-2 are rejected in a similarly efficient way. Even if nonproliferating cells are in general less immunogenic than proliferating cells (5,31), they are used for vaccination in clinical trials (34) . Although a single immunization with nonproliferating TSA cells afforded a marginal protection only, nonproliferating TSA-IL12 cells appeared to be able to elicit a stronger immune memory. Indeed, a stronger protection takes place after the rejection of engineered proliferating cells. However, proliferating TSA cells releasing IL-4, IL-10, and perhaps IFN ␥ appear to be more efficient than TSA-IL12 cells. By contrast, repeated injections of proliferating TSA-IL12 cells cure tumor-bearing mice better than do repeated injections of TSA cells engineered to produce and release any other cytokine.
Thus, the rejection of tumor cells engineered to release cytokine is not necessarily followed by an efficacious systemic immunity. Moreover, the ability to elicit an effective immunity to a subsequent challenge is not necessarily the same as promoting mechanisms that cure established tumors. In many other instances, when the immunizing and curative potentials of engineered cells have been tested in parallel, they have been shown to differ (6, 25, 27) . While proliferating TSA-IL12 cells are not particularly effective in preimmunizing, they appear to be the most effective in curing.
Evaluation of comparative data obtained with engineered tumor clones is hindered by the idiosyncrasy of each clone and the amount of the cytokine it produces. However, the clones used in this study were selected for their ability to effectively elicit a systemic immunity and not simply because they release the largest amount of cytokine [(5,6,22,23,25,27,28) ; data not shown]. The fact that the several clones releasing the same cytokine elicit similar reactivity limits the bias due to their peculiarities. In addition, the effects observed with engineered cells can also be obtained by repeated injections of exogenous cytokines at the tumor site, although with a lower efficacy (7, 8, 21, 27, 32) .
With IL-12 also, the antitumor reaction elicited when rIL-12 is injected systemically was similar to that observed against TSA-IL12 cells. In both cases, the reaction depended on CD8-positive lymphocytes and was characterized by massive macrophage infiltration; polymorphonuclear leukocytes, lymphocytes, and natural killer cells were other significant components of the reaction. The higher intensity of the reaction elicited by systemic rIL-12 is closely associated with its impressive ability to cure mice bearing established TSA-pc as well as many other tumors (15) (16) (17) (18) . This finding suggests that engineered tumor cells, while effective in eliciting an immune memory against a subsequent challenge and in curing incipient tumors, cannot compete with exogenous rIL-12 in curing established tumors.
Local rIL-12 appears to be efficacious with incipient tumors only. A larger number of mice bearing incipient TSA-pc tumors are cured following local as opposed to systemic administration of rIL-12. The local release of IL-12 by nonproliferating TSA-IL12 cells provides a similarly efficient cure. The advantage of local IL-12 disappears when the dose of rIL-12 is halved, and its efficacy disappears with established 7-day TSA-pc, probably because tumor-infiltrating leukocytes can no longer be directly activated by rIL-12.
Systemic rIL-12 activates and mobilizes tumor-alerted natural killer and T cells in virtually all lymphoid organs. After challenge, the spread of debris from incipient TSA-IL12 tumors is short-lasting and is restricted to draining lymph nodes. By contrast, from established 7-day-old TSA-pc masses, tumor antigens may easily spread to peripheral lymphoid organs and alert a larger number of natural killer and T cells that then can be triggered by systemic rIL-12 to release proinflammatory cytokines such as IFN ␥ and IL-2 (16, 20) . These cytokines are able to promote the production of TNF-␣, IL-1, and nitric oxide by macrophages and other effector cells present at the tumor site. These third-level mediators, together with the IFN ␥-dependent chemokine IP-10 and the monokine induced by IFN ␥ (MIG), contribute to the recruitment of monocytes, polymorphonuclear leukocytes, and lymphocytes observed during the rIL-12-induced shrinkage of established TSA-pc tumors (16, 20, (35) (36) (37) (38) .
These mediators may well be responsible also for vessel wall injury and tumor destruction (20, 35, 36) . Morphologic observations (Fig. 2, panel a; Fig. 7 , panels a and b), in fact, show major anomalies of the tumor microvessels. Endothelia are frequently broken, resulting in microhemorrhages in the tumor stroma and thrombosis followed by tissue necrosis. Moreover, IL-12 has been clearly shown to inhibit angiogenesis (39) . This property could well be an additional mechanism hampering the regrowth of tumor cells that escape necrosis.
The effects of IL-12 have been found to be IFN ␥ dependent in a number of models (8, 9, 11, 12, (16) (17) (18) (19) (20) 37, 38) . Evaluation of the production of IFN ␥ by lymphocytes in single mice has shown that it is associated with the intensity of IL-12-induced tumor inhibition more directly than with cytotoxic activity (19) . Depletion experiments stress the importance of CD8-positive lymphocytes in both the rejection of TSA-IL12 cells and the rIL-12-mediated cure of established TSA-pc tumors. Even so, cytokine-activated, CD8-positive lymphocytes may produce high levels of cytokines independently from their cytolytic activity (27) . In both situations, these experiments also suggest a suppressive role for CD4-positive lymphocytes, as observed in a different tumor system (14) . Moreover, as reported with several other tumors, both the inhibition of incipient TSA-IL12 tumors and the rIL-12-mediated cure of established TSA-pc tumors are impaired by anti-IFN ␥ monoclonal antibodies (data not shown).
These findings that point to a central role of IFN ␥ in IL-12-induced tumor rejection are apparently contradicted by the observation that IFN ␥-secreting tumor cells were not inhibited to the same extent as were IL-12-secreting tumor cells (22,23,28) .
Unquestionably, IFN ␥ released by engineered tumors cannot be as efficient as IFN ␥ physiologically produced as a secondary cytokine in the correct immunologic context (40) . Moreover, IL-12-induced secondary or tertiary mediators other than IFN ␥ may be critical for IL-12-elicited reactions (20, 37, 41) . One of these mediators may lead to recruitment of polymorphonuclear leukocytes into the tumor. In effect, a striking observation was that, in TSA-IFN␥ tumors, polymorphonuclear leukocytes were almost entirely absent (22) . Depletion experiments in mice treated with systemic rIL-12 underscored the critical role of polymorphonuclear leukocytes, a finding that offers further evidence of the importance of polymorphonuclear leukocyte-T-cell cross-talk in cytokine-activated regression of established tumors (32, 42) . Evidence of a direct antitumor activity on the part of polymorphonuclear leukocytes has been accumulating (23, 32) . Moreover, at the inflammation site, endothelium is highly susceptible to granulocyte-mediated injury that impairs the function of the vasculature and the underlying tissues (43) . Polymorphonuclear leukocytes are also present in incipient TSA-IL12 tumors (Fig. 2, panels c, d , and e), but the strong macrophage activation elicited by the local release of IL-12 appears to overshadow their importance.
Successful cure of established TSA-pc tumors similar to that obtained with the systemic administration of rIL-12 begun 7 days after challenge has never been even approached with TSApc tumors, either by systemic vaccination with engineered TSA cells (5) (6) (7) (21) (22) (23) (25) (26) (27) (28) or by TSA cells engineered to express B7.1 (44) or B7.2 (45) costimulatory molecules, dendritic cells pulsed with TAA peptides from TSA-pc (46) , local injection of rIL-1, rIL-2, rIL-4, rIFN ␥ (1-2,32) , or TSA cells engineered to release IL-2 (5), IL-12 (11), or fibroblasts releasing IL-12 (10) . No mice with 7-day TSA-pc tumors were cured by bolus (data not shown) or pulse administration of the maximum tolerated dose of rIL-2 (Fig. 6) .
Formation of an evident tumor mass and involvement of T lymphocytes in its rejection explain why the great majority of mice that reject established TSA-pc tumors following systemic IL-12 are protected against a subsequent TSA-pc challenge. In effect, the growth and rejection of a TSA-pc tumor are strong immunogenic signals per se (33) . However, the induction of an efficient memory when immunization with nonproliferating TSA-pc cells is associated with systemic administration of exogenous rIL-12 makes it clear that IL-12 is of greater assistance under conditions in which conventional adjuvants are ineffective.
In conclusion, it seems that the most appropriate clinical application of these data would be to use IL-12-engineered tumor cells in a minimal disease setting, i.e., when the residual burden of tumor cells remaining after surgery or cytoreductive therapy does not require the prompt elicitation of specific antitumor mechanisms. By contrast, vaccination with engineered cells is probably not the most appropriate approach to cure a patient with a small but established tumor mass. Systemic administration of exogenous rIL-12 is simpler and may provide a better cure. Any suggestions that these data could be applied in a clinical setting would have to take note of the fact that IL-12 acts immediately, whereas the immune response elicited by vaccination with TSA-IL12 cells needs at least a few days to become effective. In mice, this delay allows the tumor to grow to a point at which it can no longer be controlled by the host's immune reactions. Since human tumors grow more slowly, the difference in timing between the effects of direct administration of exogenous rIL-12 or of IL-12 released by engineered cells might be much less important.
